Research Peptides

Melanotan 1

Name: Melanotan 1
Brand: Riptide Peptides
Availability: OutOfStock

≥99% purityLyophilized powderThird-party COA

Melanotan 1 is supplied as a sterile lyophilized powder in a sealed glass vial, manufactured to ≥99% purity. Every batch is verified by independent third-party analysis and ships with a Certificate of Analysis.

$29.99

✓ Same-day dispatch
✓ Discreet packaging
✓ Third-party tested batch
✓ COA available

View Certificate of Analysis →

Certificate of analysis

The report for the current batch is available on request. Request it here.

⚠ Research use only. This product is intended solely for in-vitro laboratory research by qualified professionals. Not for human or veterinary use.

Research overview

About Melanotan 1

Melanotan 1 (MT-1, also known as Afamelanotide) is a synthetic linear tridecapeptide analog of α-melanocyte-stimulating hormone (α-MSH).

It acts as a potent agonist primarily at the melanocortin-1 receptor (MC1R). In research models, Melanotan 1 is studied for its ability to stimulate melanogenesis (melanin production), leading to increased skin pigmentation and enhanced photoprotection against UV radiation. It has been investigated for potential applications in photosensitivity disorders and skin cancer prevention models.

Key Research Areas

Skin pigmentation and melanogenesis
UV photoprotection and sun damage prevention
Photosensitivity disorders (e.g., erythropoietic protoporphyria models)
Melanocortin receptor signaling
Dermatological and pigmentation research

Molecular Profile

What Is Melanotan I?

Synthetic linear tridecapeptide analog of α-MSH

Linear Peptideα /MSH Analog

Type: Synthetic linear peptide
CAS Number: 75921-69-6
Molecular Formula: C78H111N21O19
Molecular Weight: 1646.8 g/mol
Amino Acids: 13
Sequence: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2

PubChem record →

Storage Requirements

Stability Information

Store refrigerated /Protect from light

Lyophilized (powder): 2-8°C · stable for years
Reconstituted: 2-8°C · use within 30 days

Sources & references5 peer-reviewed publications and databases

New England Journal of Medicine
Afamelanotide for Erythropoietic Protoporphyria
Langendonk JG, Balwani M, Anderson KE, et al.
2015 · DOI: 10.1056/NEJMoa1411481 · PMID: 26106947
Clinical Pharmacokinetics
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Dermatology
Minder EI, Barman-Aksoezen J, Schneider-Yin X.
2017 · DOI: 10.1007/s40262-016-0501-5 · PMID: 28063031
Journal of Drugs in Dermatology
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications
Wu R, Cotliar J.
2021 · PMID: 33683075
ClinicalTrials.gov
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
PubChem
Afamelanotide | C78H111N21O19 | CID 16197727

Research summaries and references are drawn from published, peer-reviewed literature and are provided for educational reference only. They are not product claims or medical advice. This product is sold strictly for laboratory research and is not for human or veterinary use.

Related research